Yıl: 2023 Cilt: 7 Sayı: 2 Sayfa Aralığı: 189 - 196 Metin Dili: İngilizce DOI: 10.14744/ejmo.2023.20874 İndeks Tarihi: 05-07-2023

Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance

Öz:
Objectives: The aim of this study is to investigate the prognostic impact of CXCL12 and CD44v5 on patients with ad- vanced cervical cancer. Methods: Paraffin specimens from 130 advanced cervix cancer before radiotherapy were examined using immunohis- tochemistry to test the expressions of CXCL12 and CD44v5. The correlations between the expressions of CXCL12 and CD44v5 and the five-year survival rate were analyzed. The expression changes of CXCL12 and CD44v5 in residual cancer tissues after a total radiotherapy dose of 50 Gy were tested by Real-Time PCR. Results: In the 130 patients, a significant correlation was found between CXCL12 and CD44v5 (P=0.028). The coexpres- sion occurred in 34 patients with lower five-year survival rate of 22.9%.There was no correlation between the expression of CXCL12 and CD44v5 and age, tumor stage, size, pelvic lymph node involvement and therapeutic schedule. Log-rank and multi-factor survivals analysis showed that tumor stage, lymph node involvement, CXCL12 expression, CD44v5 expression, CXCL12 and CD44v5 co-expression were independent prognostic factors. The expressions of CXCL12 and CD44 were significant elevated in residual tumor tissues, when compared to pre-radiotherapy, (p<0.05). Conclusion: A significant positive correlation occurred between the expression of CXCL12 and CD44v5. The coexpres- sion might be informative regarding poor prognosis in patients with radical radiotherapy.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Du PL, Wu KS, Fang JY, Zeng Y, Xu ZX, Tang WR, et al. Cervical cancer mortality trends in China, 1991-2013, and predictions for the future. Asian Pac J Cancer Prev 2015;16:6391–6.
  • 2. Chen T, Wei M, Liu Y, Wang H, Zhou W, Bi Y, et al. Rising mortal- ity rate of cervical cancer in younger women in urban China. J Gen Intern Med 2020;35:593.
  • 3. Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, et al. Radiotherapy of cervical cancer. Cancer Radiother 2022;26:298–308.
  • 4. Hiraoka S, Nakajima A, Kishi N, Takehana K, Hanazawa H, Matsuo Y, et al. Efficacy of local salvage therapy for recurrent uterine cervical cancer after definitive radiotherapy. Int J Clin Oncol 2021;26:1968–76.
  • 5. He S, Wang Y, Lai Y, Cao X, Ren Y, Chen Y. Concurrent chemo- radiotherapy with nedaplatin versus cisplatin in patients with stage IIB-IVA cervical cancer: a randomized phase III trial. Front Oncol 2022;11:798617.
  • 6. Kusunoki S, Kato K, Tabu K, Inagaki T, Okabe H, Kaneda H, et al. The inhibitory effect of salinomycin on the proliferation, mi- gration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol 2013;129:598–605.
  • 7. Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep 2009;22:1129–34.
  • 8. Raza S, Rajak S, Tewari A, Gupta P, Chattopadhyay N, Sinha RA, et al. Multifaceted role of chemokines in solid tumors: From biology to therapy. Semin Cancer Biol 2022;86:1105–21.
  • 9. Malik S, Westcott JM, Brekken RA, Burrows FJ. CXCL12 in Pan- creatic cancer: its function and potential as a therapeutic drug target. Cancers (Basel) 2021;14:86.
  • 10. Ahn S, Saha A, Clark R, Kolonin MG, DiGiovanni J. CXCR4 and CXCR7 signaling promotes tumor progression and obesity-as- sociated epithelial-mesenchymal transition in prostate cancer cells. Oncogene 2022;41:4633–44.
  • 11. Qin F, Pang H, Yu T, Luo Y, Dong Y. Treatment strategies and prognostic factors of 2018 FIGO Stage IIIC Cervical Cancer: A Re- view. Technol Cancer Res Treat 2022;21:15330338221086403.
  • 12. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and che - motherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–53.
  • 13. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
  • 14. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradi- ni D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Can- cer Res 2005;65:5506–11.
  • 15. López-Mateo I, Alonso-Merino E, Suarez-Cabrera C, Park JW, Cheng SY, Alemany S, et al. Thyroid hormone receptor β inhib- its self-renewal capacity of breast cancer stem cells. Thyroid 2020;30:116–32.
  • 16. Richard V, Kumar TRS, Pillai RM. Transitional dynamics of cancer stem cells in invasion and metastasis. Transl Oncol 2021;14:100909.
  • 17. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon can- cer cell capable of initiating tumour growth in immunodefi- cient mice. Nature 2007;445:106–10.
  • 18. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030–7.
  • 19. Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, et al. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Ther- anostics 2022;12:3150–77.
  • 20. Kumazawa S, Kajiyama H, Umezu T, Mizuno M, Suzuki S, Yama- moto E, et al. Possible association between stem-like hallmark and radioresistance in human cervical carcinoma cells. J Ob - stet Gynaecol Res 2014;40:1389–98.
  • 21. Ghanbarnasab Behbahani R, Danyaei A, Shogi H, Tahmasbi MJ, Saki G, Neisi N. Irradiation and conditioned media from human umbilical cord stem cells suppress epithelial-mesen- chymal transition biomarkers in breast cancer cells. Iran J Ba- sic Med Sci 2023;26:486–91.
  • 22. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;52:189–96.
  • 23. Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, et al. Targeting hypoxia sensitizes TNBC to cisplatin and pro- motes inhibition of both bulk and cancer stem cells. Int J Mol Sci 2020;21:5788.
  • 24. Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, Coniglio SJ, et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res 2012;14:R23.
  • 25. Strickland J, Garrison D, Copple BL. Hypoxia upregulates Cxcl12 in hepatocytes by a complex mechanism involving hypoxia-inducible factors and transforming growth factor-β. Cytokine 2020;127:154986.
APA FU Z, LI G, ZHONG N, WANG F (2023). Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. , 189 - 196. 10.14744/ejmo.2023.20874
Chicago FU Zhichao,LI Guo,ZHONG Nanbao,WANG Fengmei Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. (2023): 189 - 196. 10.14744/ejmo.2023.20874
MLA FU Zhichao,LI Guo,ZHONG Nanbao,WANG Fengmei Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. , 2023, ss.189 - 196. 10.14744/ejmo.2023.20874
AMA FU Z,LI G,ZHONG N,WANG F Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. . 2023; 189 - 196. 10.14744/ejmo.2023.20874
Vancouver FU Z,LI G,ZHONG N,WANG F Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. . 2023; 189 - 196. 10.14744/ejmo.2023.20874
IEEE FU Z,LI G,ZHONG N,WANG F "Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance." , ss.189 - 196, 2023. 10.14744/ejmo.2023.20874
ISNAD FU, Zhichao vd. "Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance". (2023), 189-196. https://doi.org/10.14744/ejmo.2023.20874
APA FU Z, LI G, ZHONG N, WANG F (2023). Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. Eurasian Journal of Medicine and Oncology, 7(2), 189 - 196. 10.14744/ejmo.2023.20874
Chicago FU Zhichao,LI Guo,ZHONG Nanbao,WANG Fengmei Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. Eurasian Journal of Medicine and Oncology 7, no.2 (2023): 189 - 196. 10.14744/ejmo.2023.20874
MLA FU Zhichao,LI Guo,ZHONG Nanbao,WANG Fengmei Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. Eurasian Journal of Medicine and Oncology, vol.7, no.2, 2023, ss.189 - 196. 10.14744/ejmo.2023.20874
AMA FU Z,LI G,ZHONG N,WANG F Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. Eurasian Journal of Medicine and Oncology. 2023; 7(2): 189 - 196. 10.14744/ejmo.2023.20874
Vancouver FU Z,LI G,ZHONG N,WANG F Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance. Eurasian Journal of Medicine and Oncology. 2023; 7(2): 189 - 196. 10.14744/ejmo.2023.20874
IEEE FU Z,LI G,ZHONG N,WANG F "Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance." Eurasian Journal of Medicine and Oncology, 7, ss.189 - 196, 2023. 10.14744/ejmo.2023.20874
ISNAD FU, Zhichao vd. "Prognostic Impact of Coexpressed CXCL12 and CD44v5 on Human Cervical Cancer After Radiotherapy: Stem-Like Hallmark and Radioresistance". Eurasian Journal of Medicine and Oncology 7/2 (2023), 189-196. https://doi.org/10.14744/ejmo.2023.20874